<DOC>
	<DOCNO>NCT01019174</DOCNO>
	<brief_summary>The purpose study investigate efficacy tolerability LEN/low-dose DEX continuous low-dose CY administer orally compare LEN combination low-dose DEX single CY dos IV patient relapse MM .</brief_summary>
	<brief_title>Lenalidomide/Low-dose Dexamethasone Combination With Continuous Oral Cyclophosphamide Compared Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>This open , randomize , multicenter , phase I/II study parallel group design investigate intravenous oral CY dose schedule combination LEN low-dose DEX patient refractory relapse MM . In phase I MTD CY determine use common dose escalation scheme 3 6 patient per dose level . In phase II , efficacy safety treatment regimens MTD investigate 20 patient .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Understand voluntarily sign informed consent form . 2 . Age least 18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Previously diagnose multiple myeloma base standard criterion require therapy primary refractory disease 1st 3rd relapse progressive disease ( PD ) , define 25 % increase Mprotein , development new worsen exist lytic bone lesion soft tissue plasmacytoma , hypercalcemia ( serum calcium &gt; 11.3 mg/dL ) , clinical relapse CR . 5 . At least one measurable disease manifestation define follow : For secretory multiple myeloma , measurable disease define quantifiable serum monoclonal protein value ( generally , exclusively , &gt; 1g/dL IgG Mprotein &gt; 0.5 g/dL IgA ) , applicable , urine lightchain excretion ≥ 200 mg/24 h. For oligo nonsecretory multiple myeloma , measurable disease define presence soft tissue ( bone ) plasmacytoma determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) quantifiable plasma cell infiltration bone marrow determine bone marrow biopsy . 6 . ECOG performance status equal le 2 time randomization/registration ( see Appendix I ) . 7 . Laboratory test result within range within 1 week prior randomization/registration : Absolute neutrophil count ≥ 1.5 x 109/L without use colony stimulate factor within 14 day laboratory test . Platelet count ≥ 75 x 109/L without transfusion support within 14 day laboratory test . Hemoglobin ≥ 7.5 g/dL ( regardless transfusion support prior medication erythropoietin ) . Calculated creatinine clearance ≥ 50 mL/minute . Total bilirubin equal less 1.5 mg/dL . AST ( SGOT ) ALT ( SGPT ) equal less 2,5 x ULN . Corrected serum calcium &lt; 14 mg/dL ( &lt; 3.5 mmol/L ) . 8 . Female subject childbearing potential must : Understand study medication could potential teratogenic risk Agree use , able comply , effective contraception without interruption , 4 week start study drug , throughout study drug therapy ( include dose interruption ) 4 week end study drug therapy , even amenorrhoea . This apply unless subject commits absolute continued abstinence confirm monthly basis . The following effective method contraception : Implant Levonorgestrelreleasing intrauterine system ( IUS ) Medroxyprogesterone acetate depot Tubal sterilisation Sexual intercourse vasectomise male partner ; vasectomy must confirm two negative semen analyse Ovulation inhibitory progesteroneonly pill ( i.e. , desogestrel ) Combined oral contraceptive pill recommend . If subject use combined oral contraception , must switch one method . The increase risk VTE continue 4 6 week stop combined oral contraception Prophylactic antibiotic consider time insertion particularly patient neutropenia due risk infection Agree medically supervise pregnancy test minimum sensitivity 25 mIU/ml 3 day start study medication subject effective contraception least 4 week . This requirement also apply woman childbearing potential practice complete continue abstinence . Agree medically supervise pregnancy test every 4 week include 4 week end study treatment , except case confirm tubal sterilization . These test perform 3 day start next treatment . This requirement also apply woman childbearing potential practice complete continue abstinence Male subject must Agree use condom throughout study drug therapy , dose interruption one week cessation study therapy partner childbearing potential contraception . Agree donate semen study drug therapy one week end study drug therapy . All subject must Agree abstain donate blood take study drug therapy one week follow discontinuation study drug therapy . Agree share study medication another person return unused study drug investigator . 9 . Disease free prior malignancy ≥ 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast 10 . Able willing take heparin ( usually lowmolecular weight LMWH ) low acetylsalicylic acid ( 100 mg ) daily prophylactic anticoagulation . 11 . Lifeexpectancy &gt; 3 month . EXCLUSION CRITERIA 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Females , pregnant , calculate get pregnant breast feeding ( Lactating female must agree breast feed take lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Patient currently enrol another clinical research study enrol study within 4 week randomization/registration and/or receive investigational agent reason receive agent within 4 week randomization/registration . 5 . Known hypersensitivity thalidomide , dexamethasone , cyclophosphamide similar drug . 6 . Any prior use lenalidomide . 7 . Concurrent use anticancer agent treatment . 8 . Known positive HIV infectious hepatitis , type A , B C. 9 . Any chemotherapy highdose dexamethasone within 4 week randomization/registration . 10 . Immunotherapy antibody therapy within 8 week randomization/registration . 11 . Major surgery within 4 week randomization/registration . 12 . Myocardial infarction within 6 month randomization/registration , New York Heart Association Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . 13 . Cardiac amyloidosis . 14 . Poorly control hypertension , diabetes mellitus , serious medical psychiatric illness could potentially interfere completion treatment accord protocol . 15 . Any systemic infection require treatment . 16 . Cystitis . 17 . Disturbance urinary flow . 18 . Unable unwilling take heparin ( usually lowmolecular weight LMWH ) low acetylsalicylic acid ( 100 mg ) daily prophylactic anticoagulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>